Fulcrum TherapeuticsvsMerck & Company

FULC and MRK stock compared: price, dividend, valuation and results, from SEC filings.

FULC

Fulcrum Therapeutics, Inc.

$3.69

Value $282M

-0.54%
FULC's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

Fulcrum Therapeutics (FULC) has a market value of $282M and Merck & Company (MRK) $331B. Over the last year, with dividends, FULC moved -67.9% and MRK +44.8%. Dividend yield: FULC none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    FULC$282M

    MRK$331B

    MRK is 1,173 times FULC

  • Revenue, 12 months

    FULC$0

    MRK$67.4B

  • Net income, 12 months

    FULC-$76M

    MRK$2.5B

  • Operating margin

    FULC–

    MRK–

  • ROIC

    FULC-19.2%

    MRK3.9%

    23.1 points apart

  • P/E

    FULC–

    MRK134.8

  • Dividend yield

    FULC0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    FULC-78.5%

    MRK+93.0%

    171.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

FULC-78.5%

MRK+93.0%

10020020222023202420252026
Returns by period
PeriodFULCWith dividendsMRKWith dividends
1 year since November 19, 2025-67.9%Price -67.9%+44.8%Price +40.7%
3 years since November 20, 2023-20.6%-7.4% a yearPrice -20.6%+42.7%+12.6% a yearPrice +30.2%
5 years since November 19, 2021-78.5%-26.4% a yearPrice -78.5%+93.0%+14.1% a yearPrice +65.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

FULCFulcrum TherapeuticsMRKMerck & Company

Valuation

FULCMRK
Valuation
Price$3.69$133.72
Market value$282M$331B
Enterprise value (EV)$165M$375B
P/E–134.8
P/E, 5-year median–14.8
P/B0.97.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

FULCMRK
Results and growth
Revenue, 12 months$0$67.4B
Net income, 12 months-$76M$2.5B
Free cash flow, 12 months-$65M$14.7B
Earnings per share, 12 months-$1.04$0.98
Revenue growth, year on year-100.0%1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

FULCMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin––
Net margin–3.6%
ROIC-19.2%3.9%
ROE-25.6%5.2%

Balance sheet

FULCMRK
Balance sheet
Cash$116M$9.7B
Total debt$6.8M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

FULCMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: FULC or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Fulcrum Therapeutics or Merck & Company?

By market value, Merck & Company ($331B) is about 1,173.0 times Fulcrum Therapeutics ($282M), at today's prices.

How did FULC and MRK stock do over the last 5 years?

Since November 19, 2021, FULC's price moved -78.5% and MRK's +65.7%. With dividends: FULC -78.5% (-26.4% a year), MRK +93.0% (+14.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, FULC or MRK?

The dividend yield at today's price is none for Fulcrum Therapeutics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which is the better investment, Fulcrum Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.